STING Nanoagonist Boosts Antitumor Immunity of Therapeutic DNA Vaccines
- 2 December 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 24 (49) , 15588-15597
Abstract
Therapeutic DNA cancer vaccines can stimulate specific immune responses against cancer antigens but often induce suboptimal therapeutic responses. Here, we demonstrate that a manganese-doped silica nanoparticle STING agonist (MSNA) enhances the immune response of plasmid DNA vaccines, promoting the activation and migration of distinct subsets of dendritic cell (DC) and improving antitumor immunity in three animal models. MSNA coadministered with an alpha-fetoprotein (AFP) encoded plasmid DNA (AFP-DNA) elicited significantly higher AFP-specific CD8 T cell responses than free AFP-DNA. Animals immunized with MSNA-AFP-DNA remained tumor-free in an AFP expressing hepatocellular carcinoma challenge model. MSNA combined with a DNA plasmid encoding the human papillomavirus type 16 oncoproteins E6 and E7 induced potent E7-specific CD8 T cell responses, preventing the growth of E7-expressing solid TC-1 tumors and promoting the shrinkage of E7-expressing skin grafts. These findings together demonstrate that coadministration of MSNA can improve the efficacy of therapeutic DNA vaccines targeting cancer-specific antigens.Keywords
Funding Information
- National Health and Medical Research Council (APP1107356, APP1124265, APP1125794, APP1173927)
- Australian Research Council (LE150100067)
- Science and Technology Commission of Shanghai Municipality (21PJ1404500)
- National Natural Science Foundation of China (32101146)
- Garnett Passe and Rodney Williams Memorial Foundation
- University of Queensland (UQECR2058369)
- Chinese Academy of Sciences (GJHZ2072)
- Shanghai Shuguang Program (21SG39)
- School of Medicine, Shanghai University (22820574)
- Shanghai Excellent Overseas Young Scientists
- Queensland Biomedical Assistance Fund (2017003021)
- Merchant Foundation and the Metal Manufacturing Pty Ltd
- Gallipoli Medical Research
- Zelman Cowan Academic Initiative
This publication has 34 references indexed in Scilit:
- Immunogenic Material Vaccine for Cancer Immunotherapy by Structure‐Dependent Immune Cell Trafficking and ModulationAdvanced Materials, 2024
- Biodegradable Microrobots for DNA Vaccine DeliveryAdvanced Healthcare Materials, 2023
- Recent applications of immunomodulatory biomaterials for disease immunotherapyExploration, 2022
- Rambutan-like silica nanoparticles at tailored particle sizes for plasmid DNA deliveryJournal of Materials Science, 2021
- A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC)Cancer Immunology, Immunotherapy, 2020
- The Principles of Engineering Immune Cells to Treat CancerCell, 2017
- Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinomaHepatology, 2013
- Oncofetal Antigen2008
- Slow Accumulation of Plasmid in Muscle Cells: Supporting Evidence for a Mechanism of DNA Uptake by Receptor-Mediated EndocytosisMolecular Therapy, 2001
- Presentation of the HPV16E7 Protein by Skin Grafts Is Insufficient to Allow Graft Rejection in an E7-Primed AnimalVirology, 1997